Quantitative Characterization of Glycopeptide Isomers

Information

  • Research Project
  • 10115078
  • ApplicationId
    10115078
  • Core Project Number
    R01GM130091
  • Full Project Number
    5R01GM130091-03
  • Serial Number
    130091
  • FOA Number
    PAR-17-045
  • Sub Project Id
  • Project Start Date
    2/1/2019 - 5 years ago
  • Project End Date
    1/31/2023 - a year ago
  • Program Officer Name
    BOND, MICHELLE RUEFFER
  • Budget Start Date
    2/1/2021 - 3 years ago
  • Budget End Date
    1/31/2022 - 2 years ago
  • Fiscal Year
    2021
  • Support Year
    03
  • Suffix
  • Award Notice Date
    1/22/2021 - 3 years ago
Organizations

Quantitative Characterization of Glycopeptide Isomers

Because of the pressing needs to comprehensively understand the biological attributes of glycosylation in many critical biological functions such as the immune response, cell development, cellular differentiation/adhesion and host-pathogen interactions, glycoproteomics continues to be a highly dynamic research area. Moreover, aberrant glycosylation for decades has been recognized as the attribute of many mammalian diseases, including osteoarthritis, cystic fibrosis, and cancer. The diverse biological roles of glycans and their implications in diseases have created a demand for reliable MS-based glycoproteomic approaches, permitting sensitive monitoring of glycoproteins in biological systems. We are proposing here three specific aims: Aim 1. Isomeric separation and structural identification of glycopeptides by porous graphitic columns at high temperatures coupled to post-column enzyme reactor; Aim 2. Double metabolic Stable Isotope Labeling of Glycoproteins in Cell cultures (DSILGC); and Aim 3. Develop software tools for automated identification and quantitation of glycopeptides. The outcome of these aims will be technologies that facilitate the unequivocal quantitative assessment of the isomeric microheterogenieties of glycoproteins associated with biological samples. The innovations of this proposal originate from the uniqueness of the proposed analytical methods and software. Isomeric separation of glycopeptides on PGC at high temperatures, a highly innovative method developed in our laboratory, permits the separation of all glycan isomers associated with protein glycosylation. Although enzyme reactors have been demonstrated by others, they usually used for protein digestion or glycan releasing. To our best knowledge, it is the first time a post-column reactor interfacing with MS for the characterization of isomeric glycopeptide structures is proposed (Aim 1). The simultaneous double stable isotope labeling of both proteins and glycans that we propose here will enable simultaneous analysis of glycomics, proteomics, and glycoproteomics with more accurate and effective quantitation (Aim 2). From the bioinformatics point of view, our project has several novel aspects (Aim 3). Our glycan sequencing algorithm based on HCD/CID spectra of glycopeptides reports the whole (or partial when some fragment ions are missing in the MS/MS spectra) topology of glycan (except linkages) instead of only the monosaccharide compositions that abovementioned methods can elucidate. Additionally, our algorithm can potentially identify new glycan structures, since it does not rely on previously known glycan structures. More importantly, the glycan sequencing algorithm provides complementary information to peptide identification (e.g., from CID spectra of de-glycosylated peptides or the ETD. The deliverables of this proposal are (i) analytical methods that are readily available, adaptable, and affordable to quantitively characterize and separate glycopeptide isomers and (ii) open-source software that allows automated interpretation, annotation, and quantitation of glycopeptide isomers derived from biological samples. The proposed technologies are expected to enable a better understanding of the biological attributes of glycoproteins in the development and progression of esophagus, breast and liver cancers.

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    R01
  • Administering IC
    GM
  • Application Type
    5
  • Direct Cost Amount
    213858
  • Indirect Cost Amount
    55988
  • Total Cost
    269846
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    859
  • Ed Inst. Type
    SCHOOLS OF ARTS AND SCIENCES
  • Funding ICs
    NIGMS:269846\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    EBIT
  • Study Section Name
    Enabling Bioanalytical and Imaging Technologies Study Section
  • Organization Name
    TEXAS TECH UNIVERSITY
  • Organization Department
    CHEMISTRY
  • Organization DUNS
    041367053
  • Organization City
    LUBBOCK
  • Organization State
    TX
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    794091035
  • Organization District
    UNITED STATES